Mankind is investing about ₹250-₹300 crore on the Udaipur unit that is expected to begin operations by September-October this year. The unit will manufacture dydrogesterone key starting materials, active pharmaceutical ingredients (API) and formulations.
from Latest Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/3sVau7N
https://ift.tt/Jy2Mhgo
from Latest Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/3sVau7N
https://ift.tt/Jy2Mhgo
Post a Comment